TIAA CREF Trust Co. FSB MO Cuts Position in Novartis AG (NVS)
TIAA CREF Trust Co. FSB MO cut its position in shares of Novartis AG (NYSE:NVS) by 12.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,048 shares of the company’s stock after selling 5,573 shares during the period. TIAA CREF Trust Co. FSB MO’s holdings in Novartis AG were worth $3,083,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in NVS. Integrated Investment Consultants LLC raised its stake in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares in the last quarter. Whitnell & Co. raised its stake in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares in the last quarter. Iowa State Bank bought a new position in shares of Novartis AG during the second quarter valued at approximately $122,000. M&R Capital Management Inc. bought a new position in shares of Novartis AG during the second quarter valued at approximately $122,000. Finally, WFG Advisors LP raised its position in shares of Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock valued at $134,000 after buying an additional 133 shares during the period. 9.86% of the stock is owned by institutional investors.
Shares of Novartis AG (NYSE:NVS) traded down 0.17% during mid-day trading on Tuesday, reaching $68.96. 1,829,954 shares of the company traded hands. The firm has a 50 day moving average of $72.79 and a 200-day moving average of $78.41. Novartis AG has a 52 week low of $67.28 and a 52 week high of $88.49. The stock has a market capitalization of $163.82 billion, a PE ratio of 24.32 and a beta of 0.71.
Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 25th. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.04. The firm earned $12.13 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.27 earnings per share. On average, equities research analysts expect that Novartis AG will post $4.72 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “TIAA CREF Trust Co. FSB MO Cuts Position in Novartis AG (NVS)” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2016/11/29/tiaa-cref-trust-co-fsb-mo-cuts-position-in-novartis-ag-nvs.html.
Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Tuesday. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis AG in a report on Tuesday, September 13th. Societe Generale restated a “hold” rating on shares of Novartis AG in a report on Thursday, October 27th. Argus upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Thursday, November 10th. Finally, Chardan Capital decreased their price objective on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a report on Monday, October 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $88.50.
About Novartis AG
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.